ASX - By Stock
|
NEU |
2019 FAST Summit on Angelman Syndrome
|
|
sillazze
|
1 |
1.5K |
25 |
30/12/19 |
30/12/19 |
ASX - By Stock
|
1
|
1.5K
|
25
|
|
ASX - By Stock
|
NEU |
Re:
Tightly Spring Now.
|
|
sillazze
|
117 |
95K |
4 |
10/12/19 |
10/12/19 |
ASX - By Stock
|
117
|
95K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Very little stock for sale
|
|
sillazze
|
171 |
112K |
10 |
06/12/19 |
06/12/19 |
ASX - By Stock
|
171
|
112K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Very little stock for sale
|
|
sillazze
|
171 |
112K |
21 |
05/12/19 |
05/12/19 |
ASX - By Stock
|
171
|
112K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Patent to 2034 granted in Europe for Neuren's NNZ-2591
|
|
sillazze
|
20 |
14K |
25 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
20
|
14K
|
25
|
|
ASX - By Stock
|
NEU |
FDA trial Trofinetide/Lavender
|
|
sillazze
|
24 |
25K |
18 |
01/12/19 |
01/12/19 |
ASX - By Stock
|
24
|
25K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
european patent
|
|
sillazze
|
13 |
12K |
32 |
23/11/19 |
23/11/19 |
ASX - By Stock
|
13
|
12K
|
32
|
|
ASX - By Stock
|
WFL |
Re:
Ann: OBJ Executes Agreement to acquire Nutrition Systems
|
|
sillazze
|
143 |
88K |
25 |
07/11/19 |
07/11/19 |
ASX - By Stock
|
143
|
88K
|
25
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Appendix 4C - quarterly
|
|
sillazze
|
24 |
18K |
12 |
29/10/19 |
29/10/19 |
ASX - By Stock
|
24
|
18K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Appendix 4C - quarterly
|
|
sillazze
|
24 |
18K |
8 |
18/10/19 |
18/10/19 |
ASX - By Stock
|
24
|
18K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Appendix 4C - quarterly
|
|
sillazze
|
24 |
18K |
17 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
24
|
18K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren approaching key milestones in Q4 2019
|
|
sillazze
|
145 |
75K |
13 |
09/10/19 |
09/10/19 |
ASX - By Stock
|
145
|
75K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren approaching key milestones in Q4 2019
|
|
sillazze
|
145 |
75K |
15 |
22/09/19 |
22/09/19 |
ASX - By Stock
|
145
|
75K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
CR for Acadia
|
|
sillazze
|
41 |
31K |
7 |
18/09/19 |
18/09/19 |
ASX - By Stock
|
41
|
31K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Very little stock for sale
|
|
sillazze
|
171 |
112K |
13 |
29/08/19 |
29/08/19 |
ASX - By Stock
|
171
|
112K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Very little stock for sale
|
|
sillazze
|
171 |
112K |
8 |
27/08/19 |
27/08/19 |
ASX - By Stock
|
171
|
112K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Very little stock for sale
|
|
sillazze
|
171 |
112K |
15 |
27/08/19 |
27/08/19 |
ASX - By Stock
|
171
|
112K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Loan funded shares have lapsed
|
|
sillazze
|
20 |
12K |
9 |
23/06/19 |
23/06/19 |
ASX - By Stock
|
20
|
12K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Loan funded shares have lapsed
|
|
sillazze
|
20 |
12K |
8 |
23/06/19 |
23/06/19 |
ASX - By Stock
|
20
|
12K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Loan funded shares have lapsed
|
|
sillazze
|
20 |
12K |
7 |
21/06/19 |
21/06/19 |
ASX - By Stock
|
20
|
12K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Loan funded shares have lapsed
|
|
sillazze
|
20 |
12K |
10 |
21/06/19 |
21/06/19 |
ASX - By Stock
|
20
|
12K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Goldman Sachs Healthcare Conference
|
|
sillazze
|
76 |
32K |
24 |
13/06/19 |
13/06/19 |
ASX - By Stock
|
76
|
32K
|
24
|
|
ASX - By Stock
|
NEU |
Re:
european patent
|
|
sillazze
|
13 |
12K |
22 |
11/06/19 |
11/06/19 |
ASX - By Stock
|
13
|
12K
|
22
|
|
ASX - By Stock
|
NEU |
Re:
Loan funded shares have lapsed
|
|
sillazze
|
20 |
12K |
1 |
09/06/19 |
09/06/19 |
ASX - By Stock
|
20
|
12K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Chairman's Address at 2019 Annual Meeting of Shareholders
|
|
sillazze
|
68 |
37K |
13 |
07/06/19 |
07/06/19 |
ASX - By Stock
|
68
|
37K
|
13
|
|
ASX - By Stock
|
WFL |
Re:
OBJ appoints Paul Peros as CEO of new device business
|
|
sillazze
|
302 |
138K |
18 |
06/06/19 |
06/06/19 |
ASX - By Stock
|
302
|
138K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Chairman's Address at 2019 Annual Meeting of Shareholders
|
|
sillazze
|
68 |
37K |
17 |
31/05/19 |
31/05/19 |
ASX - By Stock
|
68
|
37K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Chairman's Address at 2019 Annual Meeting of Shareholders
|
|
sillazze
|
68 |
37K |
17 |
30/05/19 |
30/05/19 |
ASX - By Stock
|
68
|
37K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
AGM
|
|
sillazze
|
38 |
19K |
5 |
30/05/19 |
30/05/19 |
ASX - By Stock
|
38
|
19K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
AGM
|
|
sillazze
|
38 |
19K |
13 |
30/05/19 |
30/05/19 |
ASX - By Stock
|
38
|
19K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Chairman's Address at 2019 Annual Meeting of Shareholders
|
|
sillazze
|
68 |
37K |
8 |
29/05/19 |
29/05/19 |
ASX - By Stock
|
68
|
37K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Chairman's Address at 2019 Annual Meeting of Shareholders
|
|
sillazze
|
68 |
37K |
10 |
28/05/19 |
28/05/19 |
ASX - By Stock
|
68
|
37K
|
10
|
|
ASX - By Stock
|
NEU |
patent USA 2591
|
|
sillazze
|
16 |
11K |
11 |
24/05/19 |
24/05/19 |
ASX - By Stock
|
16
|
11K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline
|
|
sillazze
|
89 |
53K |
3 |
22/05/19 |
22/05/19 |
ASX - By Stock
|
89
|
53K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline
|
|
sillazze
|
89 |
53K |
12 |
22/05/19 |
22/05/19 |
ASX - By Stock
|
89
|
53K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline
|
|
sillazze
|
89 |
53K |
19 |
17/05/19 |
17/05/19 |
ASX - By Stock
|
89
|
53K
|
19
|
|
ASX - By Stock
|
NEU |
Re:
Lanstead just about gone .
|
|
sillazze
|
194 |
101K |
16 |
08/05/19 |
08/05/19 |
ASX - By Stock
|
194
|
101K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
lavender
|
|
sillazze
|
7 |
6.0K |
20 |
03/05/19 |
03/05/19 |
ASX - By Stock
|
7
|
6.0K
|
20
|
|
ASX - By Stock
|
NEU |
Re:
Dr Treagus Interview
|
|
sillazze
|
49 |
23K |
9 |
05/04/19 |
05/04/19 |
ASX - By Stock
|
49
|
23K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Dr Treagus Interview
|
|
sillazze
|
49 |
23K |
17 |
04/04/19 |
04/04/19 |
ASX - By Stock
|
49
|
23K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Dr Treagus Interview
|
|
sillazze
|
49 |
23K |
22 |
03/04/19 |
03/04/19 |
ASX - By Stock
|
49
|
23K
|
22
|
|
ASX - By Stock
|
NEU |
Re:
Ann: NNZ-2591 positive effects in Phelan-McDermid syndrome model
|
|
sillazze
|
42 |
29K |
4 |
08/03/19 |
08/03/19 |
ASX - By Stock
|
42
|
29K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: NNZ-2591 positive effects in Phelan-McDermid syndrome model
|
|
sillazze
|
42 |
29K |
5 |
02/03/19 |
02/03/19 |
ASX - By Stock
|
42
|
29K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Licence Agreement: NEU & ACAD
|
|
sillazze
|
18 |
10K |
20 |
28/02/19 |
28/02/19 |
ASX - By Stock
|
18
|
10K
|
20
|
|
ASX - By Stock
|
NEU |
Re:
Ann: NNZ-2591 positive effects in Phelan-McDermid syndrome model
|
|
sillazze
|
42 |
29K |
10 |
21/02/19 |
21/02/19 |
ASX - By Stock
|
42
|
29K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Ann: NNZ-2591 positive effects in Phelan-McDermid syndrome model
|
|
sillazze
|
42 |
29K |
14 |
18/02/19 |
18/02/19 |
ASX - By Stock
|
42
|
29K
|
14
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Plans for Phase 3 trial in Rett syndrome
|
|
sillazze
|
102 |
52K |
2 |
07/02/19 |
07/02/19 |
ASX - By Stock
|
102
|
52K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren retains ex-North America, appoints investment bank
|
|
sillazze
|
84 |
37K |
22 |
01/02/19 |
01/02/19 |
ASX - By Stock
|
84
|
37K
|
22
|
|
ASX - By Stock
|
NEU |
Re:
ROW Rights
|
|
sillazze
|
163 |
83K |
2 |
01/02/19 |
01/02/19 |
ASX - By Stock
|
163
|
83K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
ROW Rights
|
|
sillazze
|
163 |
83K |
17 |
01/02/19 |
01/02/19 |
ASX - By Stock
|
163
|
83K
|
17
|
|